DE60142691D1 - Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses - Google Patents
Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebsesInfo
- Publication number
- DE60142691D1 DE60142691D1 DE60142691T DE60142691T DE60142691D1 DE 60142691 D1 DE60142691 D1 DE 60142691D1 DE 60142691 T DE60142691 T DE 60142691T DE 60142691 T DE60142691 T DE 60142691T DE 60142691 D1 DE60142691 D1 DE 60142691D1
- Authority
- DE
- Germany
- Prior art keywords
- cancer cells
- metastatic
- compositions
- metastatic potential
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 230000001394 metastastic effect Effects 0.000 title abstract 4
- 206010061289 metastatic neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000037819 metastatic cancer Diseases 0.000 title 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 101710129873 Prolyl endopeptidase FAP Proteins 0.000 abstract 1
- 230000002001 anti-metastasis Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000007878 drug screening assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 235000019833 protease Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2902—Channel shape
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2927—Rod, strand, filament or fiber including structurally defined particulate matter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2929—Bicomponent, conjugate, composite or collateral fibers or filaments [i.e., coextruded sheath-core or side-by-side type]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2929—Bicomponent, conjugate, composite or collateral fibers or filaments [i.e., coextruded sheath-core or side-by-side type]
- Y10T428/2931—Fibers or filaments nonconcentric [e.g., side-by-side or eccentric, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23151700P | 2000-09-09 | 2000-09-09 | |
PCT/US2001/026735 WO2002020825A1 (en) | 2000-09-09 | 2001-08-28 | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142691D1 true DE60142691D1 (de) | 2010-09-09 |
Family
ID=22869568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142691T Expired - Lifetime DE60142691D1 (de) | 2000-09-09 | 2001-08-28 | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses |
Country Status (9)
Country | Link |
---|---|
US (3) | US7785810B2 (de) |
EP (1) | EP1315829B1 (de) |
JP (1) | JP5433840B2 (de) |
CN (1) | CN1484709A (de) |
AT (1) | ATE475887T1 (de) |
AU (4) | AU2001288437C1 (de) |
CA (1) | CA2422162C (de) |
DE (1) | DE60142691D1 (de) |
WO (1) | WO2002020825A1 (de) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
AU2002321135B2 (en) * | 2001-06-27 | 2007-11-08 | Probiodrug Ag | Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
SK3622004A3 (sk) | 2002-02-28 | 2005-02-04 | Prosidion Limited | Inhibítory DPIV na báze glutaminylu |
ATE531257T1 (de) | 2002-09-27 | 2011-11-15 | Gen Hospital Corp | Mikrofluidische vorrichtung zur zelltrennung und verwendungen davon |
WO2004075855A2 (en) | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP2289498A1 (de) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Verwendung von Inhibioten von Glutaminyl Cyclase |
WO2005043121A2 (en) * | 2003-10-31 | 2005-05-12 | Vitatex, Inc. | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
EP1765503A2 (de) * | 2004-03-03 | 2007-03-28 | The General Hospital Corporation | System zur verabreichung einer verdünnten lösung |
US20060121624A1 (en) * | 2004-03-03 | 2006-06-08 | Huang Lotien R | Methods and systems for fluid delivery |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7754444B2 (en) | 2004-06-24 | 2010-07-13 | The Hong Kong University Of Science And Technology | Biofunctional magnetic nanoparticles for pathogen detection |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008538282A (ja) * | 2005-04-05 | 2008-10-23 | セルポイント ダイアグノスティクス, インコーポレイテッド | 装置および循環腫瘍細胞および他の粒子の濃縮および変更のための方法 |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US8778362B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
ES2804472T3 (es) | 2005-12-13 | 2021-02-08 | Harvard College | Estructuras para trasplante celular |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
EP2029779A4 (de) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US7977041B2 (en) * | 2006-06-15 | 2011-07-12 | Penelope Catherine Costello | Methods and kits for testing the efficacy of therapeutic compounds and other therapies in a three-dimensional matrix with respect to tumorous cells and tissue |
US8007991B2 (en) * | 2006-06-15 | 2011-08-30 | Penelope Catherine Costello | Three-dimensional physiological matrices for oncological testing, and methods for their production and use |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
CN101669031A (zh) * | 2007-02-27 | 2010-03-10 | 森托科隆股份公司 | 使用与细胞外标记物结合的试剂组多重检测肿瘤细胞 |
US9770535B2 (en) * | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
AU2008276251B2 (en) | 2007-07-13 | 2014-04-24 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
WO2009038754A2 (en) | 2007-09-19 | 2009-03-26 | The Research Foundation Of State University Of New York | Gene expression signatures in enriched tumor cell samples |
EP2058662A1 (de) * | 2007-10-17 | 2009-05-13 | Koninklijke Philips Electronics N.V. | Diagnose von Erkrankungen durch Messung des zellenvermittelten Abbaus der extrazellulären Matrix |
JP5591711B2 (ja) * | 2007-12-10 | 2014-09-17 | エフ.ホフマン−ラ ロシュ アーゲー | 結腸直腸癌のためのマーカーパネル |
JP5690143B2 (ja) | 2008-02-13 | 2015-03-25 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 持続的細胞プログラミング装置 |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US8008032B2 (en) * | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
CA2716826C (en) | 2008-02-25 | 2017-05-09 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
EP2952589B1 (de) | 2008-09-20 | 2018-02-14 | The Board of Trustees of The Leland Stanford Junior University | Nicht invasive diagnose von fötaler aneuploidie durch sequenzierung |
PL2881402T3 (pl) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
WO2010127782A1 (en) * | 2009-05-04 | 2010-11-11 | Roche Diagnostics Gmbh | Use of dppiv/seprase as a marker for cancer |
US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
ES2627909T3 (es) | 2009-07-15 | 2017-08-01 | Diatech Holdings, Inc. | Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos |
CA2768552A1 (en) | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
JP5716738B2 (ja) * | 2010-03-05 | 2015-05-13 | コニカミノルタ株式会社 | 細胞の検出方法及び細胞検出システム |
US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
EP3620185A1 (de) | 2010-10-06 | 2020-03-11 | President and Fellows of Harvard College | Injizierbare porenbildende hydrogele für materialbasierte zelltherapien |
EP2625528B1 (de) * | 2010-10-08 | 2016-11-23 | Cellanyx Diagnostics, LLC | Systeme und verfahren zur messung eines krebserregungs-metastasenpotenzials |
US11007528B2 (en) | 2010-10-08 | 2021-05-18 | Cellanyx Diagnostics, Llc | Systems, methods and devices for measuring growth/oncogenic and migration/metastatic potential |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
CA2826838A1 (en) * | 2011-03-11 | 2012-09-20 | F.Hoffmann-La Roche Ag | Seprase as marker for chronic obstructive pulmonary disease (copd) |
WO2012149358A1 (en) | 2011-04-28 | 2012-11-01 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2714073B1 (de) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | Krebsimpfstoff zur in-situ-antigen-erzeugung |
CN107315086B (zh) | 2011-06-29 | 2019-09-10 | 中央研究院 | 使用表面涂层对生物物质的捕获、纯化和释放 |
CN103782170A (zh) * | 2011-07-07 | 2014-05-07 | 斯克里普斯健康机构 | 分析心血管病症的方法及其用途 |
WO2013017282A1 (en) * | 2011-08-02 | 2013-02-07 | Roche Diagnostics Gmbh | In vitro tumor metastasis model |
EP2751562B1 (de) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profilierung von signalwegproteinen zur bestimmung der therapeutischen wirksamkeit |
WO2013036620A1 (en) * | 2011-09-06 | 2013-03-14 | Becton, Dickinson And Company | Methods and compositions for cytometric detection of rare target cells in a sample |
CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
ES2655842T3 (es) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR y ROS1 en el cáncer |
ES2660438T3 (es) * | 2012-11-09 | 2018-03-22 | F. Hoffmann-La Roche Ag | Captura in vitro y análisis de células tumorales circulantes |
GB2516196B (en) | 2013-01-25 | 2015-09-09 | Xcell Biosciences Inc | Methods, compositions, kits, and systems for selective enrichment of target cells |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10495644B2 (en) | 2014-04-01 | 2019-12-03 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
TW201612308A (en) | 2014-08-26 | 2016-04-01 | Academia Sinica | Collector architecture layout design |
US10286043B2 (en) | 2015-01-20 | 2019-05-14 | The Trustees Of The University Of Pennsylvania | Collagen III composition and uses |
EP3250250A4 (de) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Peritumorale und intratumorale materialien zur krebstherapie |
US10745667B2 (en) | 2015-03-23 | 2020-08-18 | Yao Tang | Methods of primary tissue culture and drug screening using autologous serum and fluids |
CN114099793A (zh) | 2015-04-10 | 2022-03-01 | 哈佛学院院长等 | 免疫细胞捕获装置及其制备和使用方法 |
JP6601768B2 (ja) * | 2015-12-02 | 2019-11-06 | 国立大学法人山形大学 | 癌細胞接着剤及び癌細胞の検出方法 |
EP3411475A4 (de) | 2016-02-06 | 2019-09-11 | President and Fellows of Harvard College | Rekapitulation der hämatopoietischen nische zur wiederherstellung der immunität |
US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
JP2019522486A (ja) | 2016-07-13 | 2019-08-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
JP6485783B2 (ja) * | 2016-09-29 | 2019-03-20 | 住友ゴム工業株式会社 | 医療用検査装置及び細胞検査方法 |
JP6779483B2 (ja) | 2016-09-29 | 2020-11-04 | 住友ゴム工業株式会社 | 医療用検査装置及び細胞検査方法 |
US10941374B2 (en) | 2016-09-29 | 2021-03-09 | Sumitomo Rubber Industries, Ltd. | Medical analysis device and cell analysis method |
JP7109719B2 (ja) | 2018-02-14 | 2022-08-01 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
JP7158671B2 (ja) * | 2018-02-14 | 2022-10-24 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
JP7064203B2 (ja) * | 2018-03-16 | 2022-05-10 | 学校法人順天堂 | 抗ヒトcd26モノクローナル抗体 |
TWI662130B (zh) * | 2018-09-21 | 2019-06-11 | 國立臺灣大學 | 分離循環癌細胞之方法 |
CN109541237A (zh) * | 2018-12-28 | 2019-03-29 | 吴江近岸蛋白质科技有限公司 | 纤维连接蛋白的生物学活性测定方法 |
US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
CN111751543A (zh) * | 2019-03-27 | 2020-10-09 | 南方医科大学南方医院 | 一种稀有肿瘤细胞富集方法及试剂盒 |
EP3995178A1 (de) * | 2020-11-09 | 2022-05-11 | Université de Genève | Verfahren |
WO2022108946A1 (en) | 2020-11-17 | 2022-05-27 | Becton, Dickinson And Company | Combined analysis of cell-free nucleic acids and single cells for oncology diagnostics |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937187A (en) * | 1983-02-04 | 1990-06-26 | Brown University Research Foundation | Methods for separating malignant cells from clinical specimens |
US4734372A (en) * | 1983-02-04 | 1988-03-29 | Brown University Research Foundation | Cell culturing methods and apparatus |
US4829000A (en) | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
US5225353A (en) * | 1986-01-30 | 1993-07-06 | Fred Hutchinson Cancer Research Center | Method for immunoselection of cells using avidin and biotin |
AU7656991A (en) | 1990-03-30 | 1991-10-30 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Method and composition for growing tumors from few cells |
US6559119B1 (en) * | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US5695998A (en) * | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
US5961923A (en) * | 1995-04-25 | 1999-10-05 | Irori | Matrices with memories and uses thereof |
IL114140A (en) * | 1995-06-14 | 2000-06-01 | Hadasit Med Res Service | Anti-metastatic and anti-angiogenetic pharmaceutical compositions |
US5840514A (en) * | 1996-11-21 | 1998-11-24 | The Regents Of The University Of Michigan | Methods of testing cancer and anticancer drugs |
WO1998036760A1 (en) * | 1997-02-20 | 1998-08-27 | Industrial Research Limited | Angiogenesis inhibitors and activators from shark cartilage |
US6428579B1 (en) * | 1998-07-01 | 2002-08-06 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
DE19833738A1 (de) * | 1998-07-27 | 2000-02-03 | Michael Giesing | Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
-
2001
- 2001-08-28 WO PCT/US2001/026735 patent/WO2002020825A1/en active Application Filing
- 2001-08-28 CA CA2422162A patent/CA2422162C/en not_active Expired - Fee Related
- 2001-08-28 AT AT01968169T patent/ATE475887T1/de not_active IP Right Cessation
- 2001-08-28 CN CNA018173535A patent/CN1484709A/zh active Pending
- 2001-08-28 EP EP01968169A patent/EP1315829B1/de not_active Expired - Lifetime
- 2001-08-28 AU AU2001288437A patent/AU2001288437C1/en not_active Ceased
- 2001-08-28 AU AU8843701A patent/AU8843701A/xx active Pending
- 2001-08-28 US US10/220,347 patent/US7785810B2/en not_active Expired - Lifetime
- 2001-08-28 JP JP2002525831A patent/JP5433840B2/ja not_active Expired - Lifetime
- 2001-08-28 DE DE60142691T patent/DE60142691D1/de not_active Expired - Lifetime
-
2004
- 2004-12-10 US US11/010,122 patent/US7687241B2/en not_active Expired - Lifetime
-
2007
- 2007-05-30 AU AU2007202486A patent/AU2007202486B2/en not_active Ceased
-
2010
- 2010-03-16 US US12/725,036 patent/US8288116B2/en not_active Expired - Lifetime
-
2011
- 2011-03-24 AU AU2011201368A patent/AU2011201368B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US20030206901A1 (en) | 2003-11-06 |
US7687241B2 (en) | 2010-03-30 |
JP2004522937A (ja) | 2004-07-29 |
AU2007202486A1 (en) | 2007-06-21 |
CN1484709A (zh) | 2004-03-24 |
EP1315829B1 (de) | 2010-07-28 |
CA2422162C (en) | 2012-10-23 |
AU2001288437C1 (en) | 2009-05-21 |
ATE475887T1 (de) | 2010-08-15 |
AU2011201368A1 (en) | 2011-04-14 |
JP5433840B2 (ja) | 2014-03-05 |
US8288116B2 (en) | 2012-10-16 |
AU8843701A (en) | 2002-03-22 |
EP1315829A1 (de) | 2003-06-04 |
AU2007202486B2 (en) | 2010-12-23 |
US20050153342A1 (en) | 2005-07-14 |
EP1315829A4 (de) | 2005-02-23 |
CA2422162A1 (en) | 2002-03-14 |
US20100173402A1 (en) | 2010-07-08 |
AU2001288437B2 (en) | 2007-06-14 |
AU2011201368B2 (en) | 2013-08-15 |
WO2002020825A1 (en) | 2002-03-14 |
US7785810B2 (en) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142691D1 (de) | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses | |
DE69528614T2 (de) | Modifizierte Proenzyme als Substrate für proteolische Enzyme | |
DE60131262D1 (en) | Ubiquitin-ligase-assay | |
DE602005013998D1 (de) | Verfahren und reagenzien zur erkennung von melanomen | |
DE69424663D1 (de) | Reporterenzym-freisetzungstechnologie: verfahren zum nachweis der gegenwart von aspartat-proteasen und anderen aktivitaeten von hydrolytischen enzymen | |
DE602004026888D1 (de) | Kinase- und phosphatasetests | |
ATE342377T1 (de) | Spezifische detektionsmedien für staphylococcus aureus und identifizierungs- und/oder zaehlmethode unter verwendung besagter detektionsmedien | |
DE69212911D1 (de) | Verfahren zum Nachweis von hydrolytischen Enzymen | |
ES2162277T3 (es) | Sustratos e inhibidores de enzimas proteoliticos. | |
ATE495243T1 (de) | Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung | |
DE602005016420D1 (de) | Verfahren und kits zur messung von adamts13/fxi-komplexen | |
ATE503021T1 (de) | Verfahren zum nachweis von endoglykosidase aktivität | |
ATE145672T1 (de) | Neue inhibitoren für hydrolytische enzyme und substrate und bestimmungsverfahren, selbige einschliessende verfahren und testsätze | |
FR2916763B1 (fr) | Nouveaux substrats de peptidase | |
WO2002038540A3 (en) | Activity-dependent cysteine protease profiling reagent | |
ATE347105T1 (de) | Verfahren, assay und kit zur quantifizierung von hiv-proteasehemmer | |
BRPI0515161A (pt) | substratos enzimáticos derivados de fenoxazinona e seu uso como revelador na detecção de microorganismos com atividade de peptidase | |
AU3221101A (en) | Detection of binding of charged species using pH- or potential-sensitive probes | |
ES8708261A1 (es) | Un procedimiento para determinar la actividad de una hidrolasa macromolecular | |
DE60236996D1 (de) | Kulturmedium zum nachweis von bakterien der gattung listeria | |
DE60334623D1 (de) | ZYKLISCHE PALLADIUM-VERBINDUNGEN MIT DAMIT KOORDINIERTEN BIS (DIPHENYLPHOSPHIN)-FERROCEN-LIGANDEN ZUR HEMMUNG DER AKTIVITuT VON PROTEINEN UND ENZYMEN UND BEHANDLUNG VON DAMIT ZUSAMMENHuNGENDEN KRANKHEITEN UND ST RUNGEN. | |
DE60331414D1 (de) | Aggrecanase-1- und -2-peptidsubstrate und verfahren | |
DE60109581D1 (de) | Verfahren zur evaluierung von inplantierbaren materialien | |
WO2004042352A3 (en) | Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates | |
NO20020379D0 (no) | Epoksid-hydrolaser fra Streptomyces |